MILAN, Italy—Genomic profiling could help reduce the risk of over-treatment in primary prostate cancer (PC) by identifying patients and healthy individuals whose genes put them at greatest risk of developing dangerous disseminated disease said Norman J Maitland PhD, Professor of Molecular Biology and Director of the Cancer Research Unit at York University, UK. He was speaking at the 2016 European Multidisciplinary Meeting on Urological Cancers (EMUC).
He interpreted data from several recent studies—investigating the influence gene mutations had on prostate tumor development—that infer gene arrays could soon distinguish patients with dangerous tumors from those whose disease does not need aggressive management.
He discusses his findings n the Audio Journal of Oncology Interview with Peter Goodwin: “We don’t know which [patients] are going to die of prostate cancer and which ones can be left untreated for the rest of their lives,” he said. “Genetics is one tool to allow us to understand that.”